What happened with DSGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Design Therapeutics is developing medicines for people with genetic diseases caused by excessively repeated DNA sequences. Its GeneTAC small molecules are designed to change how affected genes are expressed, addressing the underlying disease mechanism. Programs include DT-216P2 for Friedreich’s ataxia and DT-168, designed as eye drops for Fuchs endothelial corneal dystrophy, a disease affecting the cornea.
The company has candidates in clinical trials, but none is approved for sale. It funds development with capital raised from investors rather than medicine sales and expects to need additional financing. Future product revenue depends on demonstrating safety and effectiveness, obtaining regulatory approval, and securing payment from insurers or patients. It cannot market its candidates in the United States without FDA approval.
All its programs use GeneTAC, so the business depends on this shared approach succeeding. Important technology is licensed from the Wisconsin Alumni Research Foundation (WARF); keeping those rights requires meeting development and contractual obligations, and licensed-product sales would carry royalties. Design Therapeutics also relies on outside manufacturers, including a sole supplier for one component of DT-216P2.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Design Therapeutics’ prospects hinge on clinically validating its GeneTAC programs while keeping its foundational patent license from Wisconsin Alumni Research Foundation.
Larimar Therapeutics, Inc. is a direct rival to Design Therapeutics in Friedreich’s ataxia, concentrating its resources on nomlabofusp while Design advances DT-216P2. Larimar has no revenue yet; nomlabofusp’s clinical progress is the news to watch for Design’s competing treatment.
Lexeo Therapeutics, Inc. overlaps with Design Therapeutics’ Friedreich’s ataxia opportunity by developing an FXN gene therapy aimed at the heart, rather than Design’s small-molecule treatment. Watch its progress in treating the disease’s cardiac manifestations, the specific part of this patient population Lexeo targets.
Solid Biosciences Inc. competes with Design Therapeutics’ small-molecule Friedreich’s ataxia program through an FXN gene-replacement approach. Its SGT-212 development news, rather than its other neuromuscular and cardiac programs, is the relevant signal for Design.
Biogen Inc. already sells SKYCLARYS for Friedreich’s ataxia, setting the commercial treatment benchmark for Design Therapeutics’ DT-216P2. Watch SKYCLARYS in adults and adolescents aged 16 and older, its approved patient group, rather than Biogen’s broader drug sales.
Dyne Therapeutics, Inc. competes with Design Therapeutics’ DT-818 to treat the underlying genetic cause of myotonic dystrophy type 1 (DM1), using an antibody-linked oligonucleotide rather than a small molecule. Watch z-basivarsen’s development: Dyne’s spending on that DM1 program rose from $74.082 million in 2024 to $145.077 million in 2025.
PTC Therapeutics, Inc. overlaps with Design Therapeutics in two diseases: vatiquinone targets Friedreich’s ataxia, while its Huntington’s disease drug, licensed to Novartis, changes how RNA is spliced. For Design’s FA program, watch vatiquinone’s regulatory path: after the FDA’s 2025 rejection, PTC was told an additional study would be needed for resubmission.
PepGen Inc. competes with Design Therapeutics’ DT-818 in DM1 by targeting genetic repeats with an oligonucleotide rather than a small molecule. PepGen reported no revenue in 2025; its clinical-stage CUG-repeat program EDODM1 is the development to watch against Design’s approach.
Entrada Therapeutics, Inc.’s VX-670 competes with Design Therapeutics’ DT-818 in DM1, but Vertex holds the worldwide license and leads development outside Entrada’s collaboration research. Vertex funds Entrada’s research and pays it milestones, making VX-670’s clinical advancement the relevant news rather than Entrada’s own product sales.
Wave Life Sciences Ltd. competes with Design Therapeutics in Huntington’s disease through an antisense RNA therapy, while Design aims to reduce production from the mutant HTT gene. Watch Wave’s HD clinical progress separately from its collaboration revenue: all 2025 revenue came from GSK after the Takeda HD-program license ended in October 2024.
Voyager Therapeutics, Inc.’s gene therapy developed with Neurocrine competes with Design Therapeutics’ small-molecule treatment for Friedreich’s ataxia. Watch that preclinical program’s progress; Voyager receives partner fees and milestone payments across its portfolio, so its total partnership funding does not measure this FA program alone.
Sarepta Therapeutics competes with Design Therapeutics in both DM1 and Huntington’s disease through licensed RNA-interference and siRNA programs. Watch those programs rather than Sarepta’s product-sales total, which covers its business selling approved Duchenne treatments, not these competing development opportunities.
Novartis AG competes with Design Therapeutics across DM1 and Huntington’s disease through Avidity’s DM1 program, which it owns, and PTC’s HD splicing modifier, which it licenses. Watch those two programs’ development rather than Novartis’s worldwide prescription-medicine sales for a read on Design’s competition.
Biogen Inc. earningsBIIB
Biogen's report can show how patients are using SKYCLARYS for Friedreich's ataxia, the established treatment benchmark for Design Therapeutics' DT-216P2.
Look for Biogen's disclosures on SKYCLARYS sales or use, not its total drug sales. Rising use would show demand for treatment in this patient group, but DT-216P2 would face a standard set by an approved medicine; limited use could also signal access or acceptance hurdles, not that patients will switch to Design Therapeutics. The takeaway is how much demand exists and what barriers a new treatment would face.
Fed Interest Rate Decision
For Design Therapeutics, the Fed’s policy rate—the benchmark that influences borrowing rates—can affect interest earned on its cash and short-term investments and the cost of borrowing to fund research and clinical trials.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may increase interest income as Design Therapeutics reinvests cash and short-term investments, but could also raise the cost of new borrowing to fund its programs.
If it comes in below expectations
Lower rates may reduce interest income as Design Therapeutics reinvests cash and short-term investments, but could also lower the cost of new borrowing to fund its programs.
Design Therapeutics, Inc. earningsThis company
Design Therapeutics has no approved products, so this report will show whether research spending and cash use remain supportable as it develops its candidates.
Read research and development expense alongside cash used in operating activities and cash and investments at period end: expense shows the work charged to the business, while operating cash use shows how quickly cash is leaving, and the two are not identical. If cash use stays controlled while resources can still support programs such as DT-216P2 and DT-168, Design Therapeutics has room to keep developing them; if cash use accelerates and the reserve thins, financing or changes to research plans become more pressing. Design Therapeutics does not allocate internal research and development costs by program, so the total cannot show exactly what each program cost. The conclusion is whether available resources can keep funding development.
Dyne Therapeutics, Inc. earningsDYN
Dyne Therapeutics' report can show how far z-basivarsen has advanced as it competes with Design Therapeutics' DT-818 in DM1.
Watch z-basivarsen's clinical progress rather than treating Dyne's total research spending as a measure of this one program. If it advances, Design Therapeutics' DT-818 faces a more tangible competing approach in DM1; if it stalls or hits a setback, near-term pressure eases, but that does not show DT-818 works. The takeaway is whether a rival treatment path is moving forward.
Larimar Therapeutics, Inc. earningsLRMR
Larimar Therapeutics' report can show whether its nomlabofusp program is advancing as a direct rival to Design Therapeutics' DT-216P2 in Friedreich's ataxia.
Watch nomlabofusp's clinical progress, not Larimar's lack of product-sales revenue, to judge this treatment program. If development advances, patients with Friedreich's ataxia could have another treatment competing with DT-216P2; if it is delayed or hits a setback, near-term pressure eases, but that does not prove Design Therapeutics' candidate works. The takeaway is whether this direct rival is closing the development gap.
Wave Life Sciences Ltd. earningsWVE
Wave Life Sciences' report can show whether its Huntington's disease program is advancing, a more relevant signal for its competition with Design Therapeutics than collaboration revenue.
Separate progress in Wave Life Sciences' Huntington's disease program from its revenue under the GSK collaboration; collaboration revenue does not show how far this program has advanced. Clinical progress would make another treatment approach more tangible competition for Design Therapeutics; a stall or setback would ease near-term pressure but would not establish that Design's approach works. The takeaway is whether the competing approach is moving through clinical development.
